The Cost-effectiveness of Analogue Insulin Pens in Comparison with Human Insulin Pens for Controlling Type 1, Type 2, and Gestational Diabetes: A Systematic Review Article

Pakdaman, Mohsen; Akbari, Rahele; Dehghan, Habibollah; Valagohar, Reza; Rostami, Parastoo; Namayandeh, Mahdieh

doi:10.5812/htaa.86421

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Individual and public health is the most important aspect of human life (Sadock and Sadock, 2011). Diabetes is the most prevalent disease caused by metabolic disorders and the fifth leading cause of mortality in Western societies (Pakdaman et al , 2020). It is one of the most common chronic diseases worldwide and its incidence is consistently increasing (Mansourghanaei et al , 2005).…”

Section: Introductionmentioning

confidence: 99%

The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran

Pakdaman

Akbari

Dehghan

et al. 2020

IJHCQA

Self Cite

View full text Add to dashboard Cite

PurposeFor years, traditional techniques have been used for diabetes treatment. There are two major types of insulin: insulin analogs and regular insulin. Insulin analogs are similar to regular insulin and lead to changes in pharmacokinetic and pharmacodynamic properties. The purpose of the present research was to determine the cost-effectiveness of insulin analogs versus regular insulin for diabetes control in Yazd Diabetes Center in 2017.Design/methodology/approachIn this descriptive–analytical research, the cost-effectiveness index was used to compare insulin analogs and regular insulin (pen/vial) for treatment of diabetes. Data were analyzed in the TreeAge Software and a decision tree was constructed. A 10% discount rate was used for ICER sensitivity analysis. Cost-effectiveness was examined from a provider's perspective.FindingsQALY was calculated to be 0.2 for diabetic patients using insulin analogs and 0.05 for those using regular insulin. The average cost was $3.228 for analog users and $1.826 for regular insulin users. An ICER of $0.093506/QALY was obtained. The present findings suggest that insulin analogs are more cost-effective than regular insulin.Originality/valueThis study was conducted using a cost-effectiveness analysis to evaluate insulin analogs versus regular insulin in controlling diabetes. The results of study are helpful to the government to allocate more resources to apply the cost-effective method of the treatment and to protect patients with diabetes from the high cost of treatment.

show abstract

Section: Introductionmentioning

confidence: 99%